Louvain-la-Neuve, Belgium, 04 April, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, will be hosting a Capital Markets Day (CMD) this coming ...

Mesoblast develops allogeneic products based on its proprietary remestemcel-L and rexlemestrocel-L mesenchymal lineage stromal and precursor cell platform technologies. Its allogeneic cellular ...

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results and ...

Ms. Whitaker is an accomplished C-suite leader, most recently as Chair and CEO of Aerami Therapeutics Holdings Inc. During her executive career she has held senior leadership roles at GlaxoSmithKline ...

Praxis management will also be participating in the Piper Sandler Spring Biopharma Symposium, taking place at One Boston Place in Boston on Thursday, April 17, 2025.

The inducement grant consisted of time-based restricted stock units (“RSUs”) for 8,400 shares of Intellia’s common stock, with one-third of such RSUs vesting on April 1, 2026, 2027 and 2028.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological ...

The Company is pleased to announce the Mr. Daniel Bloch, a current director of the Company has joined the audit committee of Vaxil, effective immediately. The audit committee now comprises Dr. Ari ...

Cohealyx expands AVITA Medical’s therapeutic wound care portfolio, complementing its flagship product, the RECELL ® System, which is FDA-approved for the treatment of thermal burns and full-thickness ...

Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination therapy ...

CHASKA, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today ...

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S.